Table 1 Summary of reported CD19-negative relapse in trials of anti-CD19 CAR-T cells for B-ALL
Treating institute | Patient populations | Construct (scFv-Hinge-TM-CD-SD) | Gene transfer method | Conditioning therapy | Infused cell dose | Responses observed | Reported relapse |
|---|---|---|---|---|---|---|---|
MSKCC [26] | Adult 33 32 evaluable for response | SJ25C1-CD28-CD3ζ | Retrovirus | Cy or Cy/Flu | 1–3 × 106 CAR+ T cells/kg | CR: 29/32 (91%) | 14 relapse with 2 CD19− relapse |
Upenn [24] | Pediatric and young adult 59 | FMC63-CD8α-4-1BB-CD3ζ | Lentivirus | Investigator’s choice | 107–108 cells/kg with a transduction efficiency of 2.3–45% | CR: 55/59 (93%) | 20 relapse with 13 CD19− relapse |
NCI [25] | Young adult 38 | FMC63-CD28-CD3ζ | Retrovirus | Cy/Flu or FLAG or IE | 1 or 3 × 106 CAR+ T cells/kg | CR: 23/38 (61%) | 2 CD19− relapse |
FHCRC [5] | Adult 30 29 evaluable for response | FMC63-IgG4 CD28-4-1BB-CD3ζ | Lentivirus | Cy ± etoposide or Cy/Flu | 2 × 105 or 2 × 106 or 2 × 107 CAR+ T cells/kg (1:1 CD4+:CD8+) | CR: 27/29 (93%) | 9 relapse with 2 CD19− relapse |